CCIA
TEVA icon

Campbell & Co Investment Adviser’s Teva Pharmaceuticals TEVA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-75,565
Closed -$569K – 1189
2023
Q2 		$569K Buy
+75,565
New +$613K 0.1% 368
2015
Q4 		– Sell
-8,400
Closed -$474K – 227
2015
Q3 		$474K Buy
+8,400
New +$545K 0.32% 112
2015
Q1 		– Sell
-3,538
Closed -$203K – 279
2014
Q4 		$203K Buy
+3,538
New +$197K 0.13% 194

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Campbell & Co Investment Adviser's TEVA Position: Q3 2023 in Review

Campbell & Co Investment Adviser sold out of Teva Pharmaceuticals (TEVA) in Q3 2023, closing a stake of 75,565 shares — an estimated $569K sold.

Campbell & Co Investment Adviser first reported a position in TEVA in Q4 2014 and held it in 3 quarters. The position peaked at $569K in Q2 2023. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

  • Campbell & Co Investment Adviser reported no remaining Teva Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 75,565 Teva Pharmaceuticals shares in Q3 2023, an estimated $569K.
  • Campbell & Co Investment Adviser first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Teva Pharmaceuticals position peaked at $569K in Q2 2023.
  • 435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2023, filed 8 Nov 2023.